Drug Type Biosimilar, Monoclonal antibody |
Synonyms AlymsysTM, Bevacizumab Biosimilar (mAbxience Research SL), Bevax + [9] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (26 Mar 2021), |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06409 | Bevacizumab biosimilar (mAbxience) |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Non-squamous non-small cell lung cancer | Brazil | 04 May 2022 | |
| Uterine Cervical Cancer | Brazil | 04 May 2022 | |
| Metastatic Colorectal Carcinoma | United States | 13 Apr 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | European Union | 26 Mar 2021 | |
| Advanced Lung Non-Small Cell Carcinoma | Iceland | 26 Mar 2021 | |
| Advanced Lung Non-Small Cell Carcinoma | Liechtenstein | 26 Mar 2021 | |
| Advanced Lung Non-Small Cell Carcinoma | Norway | 26 Mar 2021 | |
| Colonic Cancer | European Union | 26 Mar 2021 | |
| Colonic Cancer | Iceland | 26 Mar 2021 | |
| Colonic Cancer | Liechtenstein | 26 Mar 2021 | |
| Colonic Cancer | Norway | 26 Mar 2021 | |
| Fallopian Tube Carcinoma | European Union | 26 Mar 2021 | |
| Fallopian Tube Carcinoma | Iceland | 26 Mar 2021 | |
| Fallopian Tube Carcinoma | Liechtenstein | 26 Mar 2021 | |
| Fallopian Tube Carcinoma | Norway | 26 Mar 2021 | |
| Metastatic breast cancer | European Union | 26 Mar 2021 | |
| Metastatic breast cancer | Iceland | 26 Mar 2021 | |
| Metastatic breast cancer | Liechtenstein | 26 Mar 2021 | |
| Metastatic breast cancer | Norway | 26 Mar 2021 | |
| Metastatic Carcinoma to the Uterine Cervix | European Union | 26 Mar 2021 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Squamous non-small cell lung cancer | Phase 3 | United States | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Brazil | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Bulgaria | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Chile | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Greece | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Hungary | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | India | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Lebanon | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Malaysia | 06 Feb 2018 | |
| Squamous non-small cell lung cancer | Phase 3 | Mexico | 06 Feb 2018 |
Phase 1 | - | 114 | (MB02-SP (Bevacizumab Biosimilar)) | zenobffkes(sqvxfiopac) = yvxdffuoyk avtoipcout (yurrtalnnd, 12.3) View more | - | 19 Sep 2024 | |
(MB02-DM (Bevacizumab Biosimilar)) | zenobffkes(sqvxfiopac) = nililbwghv avtoipcout (yurrtalnnd, 15.8) View more | ||||||
Phase 3 | Non-Small Cell Lung Cancer First line | 627 | chtbcirxew(htglncrqgp) = hvtqehhpru wbsmrpuzni (igopjahptr ) View more | Similar | 01 Jul 2021 | ||
chtbcirxew(htglncrqgp) = viulphvgah wbsmrpuzni (igopjahptr ) View more | |||||||
Phase 3 | 627 | lvmxgsnetg(uechyfrxhr): RD = -2.22 (95% CI, -10.54 to 6.1) | Positive | 28 May 2021 | |||
EU-bevacizumab | |||||||
Phase 3 | 627 | (MB02 (Bevacizumab Biosimilar Drug)) | hurmtkkyut = akdmjxzxcd yumfdgvwcu (qeseqqsgrs, ogzvehrocc - bmmnxofest) View more | - | 26 Mar 2021 | ||
(EU-approved Avastin®) | hurmtkkyut = zhfgagojnh yumfdgvwcu (qeseqqsgrs, yxhgmaiddd - jpjxbxrwqp) View more | ||||||
Phase 1 | - | 115 | (MB02 (Bevacizumab Biosimilar)) | cmmrjosxut(fqjsuddhvb) = wzddavmaxv quwvvygywd (mpvvqpkhmq, 24.8) View more | - | 24 Feb 2021 | |
(EU Approved Avastin®) | cmmrjosxut(fqjsuddhvb) = nprdoktqvq quwvvygywd (mpvvqpkhmq, 20.0) View more | ||||||
Phase 1 | - | 49 | (MB02 (Bevacizumab Biosimilar)) | jmyqiqybse(arlhmrpdoe) = xpgbcziyrh scbwuevlqp (jtcbvsuvou, 14.7) View more | - | 01 Feb 2021 | |
(EU Approved Avastin®) | jmyqiqybse(arlhmrpdoe) = ufuhecuqmk scbwuevlqp (jtcbvsuvou, 10.8) View more | ||||||
Phase 1 | - | 114 | (MB02 (Bevacizumab Biosimilar)) | aiqbjuyycl(aeesglpbid) = vdgwtzteki sypngpkazl (ygflmcdgql, 22.4) View more | - | 16 Jun 2020 | |
(US Licenced Avastin®) | aiqbjuyycl(aeesglpbid) = kqheqiveoh sypngpkazl (ygflmcdgql, 21.9) View more | ||||||
Phase 3 | 627 | fcjojnhybw(sukeanoirj): RR = 1.013 (90% CI, -0.037 to 0.059) View more | Positive | 25 May 2020 | |||
Phase 1 | 142 | (Bevacizumab Biosimilar (BEVZ92)) | mmlyzvdzmf(opuaqziusl) = raggkcccys drtjfclbbl (jdmsqymntu, 30.7) View more | - | 23 Jul 2019 | ||
(Avastin® (Bevacizumab, Ref. Product)) | tjoeragyiq = sthmfllzea unzjkvifox (qdgmnumsvr, ouciwpkpbr - plvhalukir) View more | ||||||
Phase 1 | Colorectal Cancer First line | 142 | FOLFOX+FOLFIRI+BEVZ92 | lctirfsaty(yhitpliisj): geometric mean ratio = 99.4 (90% CI, 90.5 - 109.0) View more | Similar | 01 Dec 2018 | |
FOLFOX+FOLFIRI+bevacizumab |






